Efficacy of anti-RANKL antibody on bone and mineral disorders in post-kidney transplant patients.

Efficacy of anti-RANKL antibody on bone and mineral disorders in post-kidney transplant patients. - Anti-RANKL antibody after kidney transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013268

Enrollment

Registered

2014-04-01

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone and mineral disorders after kidney transplantation

Interventions

Treatment with ani-RANKL antibody on new kidney transplant recipient

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: New kidney transplant recipient

Exclusion criteria

Exclusion criteria: Person incapable of giving informed consent

Design outcomes

Primary

Measure	Time frame
Bone mineral density at lumbar vertebrae and femoral neck	—

Secondary

Measure	Time frame
Clinical fracture, bone turn over marker, adverse side effect	—

Countries

Japan

Contacts

Public ContactAtsushi Suzuki

Fujita Health University Deparment of Endocrinology and Metabolism

aslapin@fujita-hu.ac.jp0562-93-2139

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026